Immunitas Therapeutics

Immunitas uses a unique combination of single-cell genomics and machine learning to identify key immune cells that play a significant role in immuno-oncology. Single-cell genomics is a technology that allows scientists to study individual cells, while machine learning is a type of artificial intelligence that enables computers to learn from data.

The company also has its own therapeutic discovery process, which involves the use of antibody display and immunization. Antibody display is a method used to identify potential new drugs, while immunization is the process of making a person immune to an infection.

Immunitas' business model revolves around the research and development of new cancer treatments. The company's main source of revenue comes from the development and commercialization of these treatments. Currently, their lead program for solid tumor and hematological malignancies is in clinical trials.

The company was founded by a team of renowned cancer research and therapeutic antibody pioneers from prestigious institutions such as the Dana Farber Cancer Institute, Mass General Cancer Center, the Broad Institute, and MIT.

Immunitas places a high value on innovation and collaboration, and believes in fostering a culture of scientific exploration. The company's research is based on human data, which allows them to stay closer to the most relevant and translatable biology for patients.